FDA teams with academia on nanotech
This article was originally published in The Rose Sheet
Executive Summary
FDA collaborates with the Alliance for NanoHealth to hasten development of novel medical products using nanotechnology. The FDA/ANH Nanotechnology Initiative aims to expand understanding of how nanoparticles affect biologic systems and develop processes to potentially mitigate nanotech-related risks, all of which will be placed in the public domain. FDA said March 10 the collaboration is part of its Critical Path initiative for biomarker validation, better clinical trial design and new manufacturing methods